DE2325072A1 - Arzneimittel auf der basis von lysinderivaten zur bekaempfung der leukopenie - Google Patents
Arzneimittel auf der basis von lysinderivaten zur bekaempfung der leukopenieInfo
- Publication number
- DE2325072A1 DE2325072A1 DE2325072A DE2325072A DE2325072A1 DE 2325072 A1 DE2325072 A1 DE 2325072A1 DE 2325072 A DE2325072 A DE 2325072A DE 2325072 A DE2325072 A DE 2325072A DE 2325072 A1 DE2325072 A1 DE 2325072A1
- Authority
- DE
- Germany
- Prior art keywords
- lysine
- combating
- leucopenia
- treatment
- products based
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000002364 leukopenia Diseases 0.000 title claims description 4
- 150000002668 lysine derivatives Chemical class 0.000 title claims description 4
- 229940126601 medicinal product Drugs 0.000 title description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940014662 pantothenate Drugs 0.000 claims description 7
- 235000019161 pantothenic acid Nutrition 0.000 claims description 7
- 239000011713 pantothenic acid Substances 0.000 claims description 7
- 210000000952 spleen Anatomy 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 3
- 231100001022 leukopenia Toxicity 0.000 claims description 3
- 102000011931 Nucleoproteins Human genes 0.000 claims description 2
- 108010061100 Nucleoproteins Proteins 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 description 10
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241001539473 Euphoria Species 0.000 description 3
- 206010015535 Euphoric mood Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7218165A FR2201879B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1972-05-19 | 1972-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2325072A1 true DE2325072A1 (de) | 1973-11-29 |
Family
ID=9098874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2325072A Pending DE2325072A1 (de) | 1972-05-19 | 1973-05-17 | Arzneimittel auf der basis von lysinderivaten zur bekaempfung der leukopenie |
Country Status (5)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2723451A1 (de) * | 1976-06-03 | 1977-12-22 | Mirko Beljanski | Polyribonucleotide, verfahren zu ihrer herstellung und ihre verwendung als oder in arzneimitteln |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59219235A (ja) * | 1983-05-30 | 1984-12-10 | Mitsui Toatsu Chem Inc | 消化性潰瘍用剤 |
| HU213677B (en) * | 1993-11-09 | 1997-12-29 | Immunal Kft | Pharmaceutical compositions for preventing and treating tumor diseases, and process for producing them |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2036101A5 (en) * | 1969-03-04 | 1970-12-24 | Tixier Georges | Lysine pantothenate prepn, pharmaceutical |
-
1972
- 1972-05-19 FR FR7218165A patent/FR2201879B2/fr not_active Expired
-
1973
- 1973-05-07 BE BE130843A patent/BE799209R/xx active
- 1973-05-09 US US358694A patent/US3885030A/en not_active Expired - Lifetime
- 1973-05-14 GB GB2280973A patent/GB1388522A/en not_active Expired
- 1973-05-17 DE DE2325072A patent/DE2325072A1/de active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2723451A1 (de) * | 1976-06-03 | 1977-12-22 | Mirko Beljanski | Polyribonucleotide, verfahren zu ihrer herstellung und ihre verwendung als oder in arzneimitteln |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2201879B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-01-23 |
| US3885030A (en) | 1975-05-20 |
| BE799209R (fr) | 1973-08-31 |
| GB1388522A (en) | 1975-03-26 |
| FR2201879A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1902227A1 (de) | Arzneimittel zur psychotherapeutischen Anwendung und Verfahren zu seiner Herstellung | |
| DE69201660T2 (de) | Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma. | |
| DE3234537C2 (de) | Verwendung von 3-(2,2,2-Trimethylhydrazinium)propionatdihydrat zur Behandlung kardiovaskulärer Erkrankungen | |
| DE60124516T2 (de) | Kombination des lezithins mit ascorbinsäure | |
| EP1283047A1 (de) | Methode zur herstellung einer bioaktiven substanz aus blutserum | |
| DE2325072A1 (de) | Arzneimittel auf der basis von lysinderivaten zur bekaempfung der leukopenie | |
| WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE69005909T2 (de) | Mischung von Vitamin A in physiologischer Dosis und verschiedenen Wirkstoffen mit therapeutischer Wirksamkeit. | |
| DE3707532C2 (de) | Verwendung einer Kombination von Extr. Gingko biloba oder mindestens einem Gingkolid und Acetylsalicylsäure oder DL-Lysin-mono-acetylsalicylat oder Diflunisal zur Behandlung von Verbrennungen, Verbrühungen, Strahlenschäden und Erfrierungen | |
| DE2250032B2 (de) | Arzneimittel auf der Basis von Lysinderivaten zur Bekämpfung der Leukopenie und zur Normalisierung der prozentualen Zusammensetzung des Leukocytenbildes | |
| EP2796143B1 (de) | Pharmazeutisches homöopathisches Arzneimittel zur Gewichtsreduktion | |
| EP2548564B1 (de) | Pharmazeutisches Mittel, Ernährung für einen Patienten sowie Verfahren zur Gewichtsreduzierung | |
| DE69922808T2 (de) | Antivirale Zusammensetzungen enthaltend Yohimbin als therapeutischen Wirkstoff | |
| AT402691B (de) | Verwendung von galanthamin zum herstellen von arzneimitteln zur behandlung von trisomie 21 oder verwandter trisomie-syndrome | |
| DE2352618A1 (de) | Arzneimittel zur behandlung des parkinsonismus | |
| EP0241498B1 (de) | Schmerzstillendes und entzündungshemmendes arzneimittel auf pflanzlicher basis | |
| Kaikade et al. | Kamal Patra as an Antidote in Dhatura Poisoning in Albino Mice-in Vivo Study | |
| DE68908757T2 (de) | 5-Methoxypsoralen gegen Depressionen. | |
| AT516952B1 (de) | Arzneimittel | |
| DE2908127A1 (de) | Verwendung von inhibitoren des abbaus von enkephalinen und endorphinen bei der bekaempfung von schmerzzustaenden sowie zur herstellung pharmazeutischer zubereitungen und arzneimittel | |
| DE2015877A1 (de) | Arzneimittel | |
| WO2006029605A1 (de) | Verfahren und wirkstoff zur bekämpfung von plasmodien | |
| Prajapat et al. | Diabetic Wound Healing Potential of Eclipta alba gel in diabetic rodent model. | |
| DE19739763A1 (de) | Vitamin B3/Niacin zur Behandlung von Krankheiten | |
| DE4123427A1 (de) | Verwendung eines kava-extraktes und seiner inhaltsstoffe |